🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,413 results for “Chinese” Clear

  1. raltitrexed combined with apatinib

    Chinese PLA General Hospital

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  2. recombinant human erythropoietin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hypoxic-Ischemic Encephalopathy

    phase 2 small molecule completed

    1 trial

  3. recombinant human erythropoietin (rhEpo)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Infant, Premature

    phase 2 small molecule active

    1 trial

  4. rhGM-CSF

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pulmonary Alveolar Proteinosis

    phase 2 small molecule active

    1 trial

  5. rituximab

    Chinese University of Hong Kong

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  6. sarcosine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  7. self-expandable 125I radioactive seeds-loaded-stent

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cholangiocellular Carcinoma

    phase 2 other completed

    1 trial

  8. sintilimab+IBI310+chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC Stage II

    phase 2 small molecule active

    1 trial

  9. sintiliman plus LDRT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  10. split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Influenza

    phase 2 mab completed

    2 trials

  11. standard triple region

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Helicobacter Pylori Infection

    phase 2 small molecule completed

    1 trial

  12. the standard "3+7" regimen

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Newly Diagnosed Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  13. tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stage III

    phase 2 small molecule active

    1 trial

  14. tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric

    phase 2 small molecule active

    1 trial

  15. umbilical cord mesenchymal stem cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral Arterial Disease

    phase 2 mab completed

    1 trial

  16. umbilical cord mesenchymal stem cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cartilage Damage

    phase 2 mab active

    1 trial

  17. vitamin C

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  18. zanubrutinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Antiphospholipid Syndrome

    phase 2 small molecule active

    1 trial

  19. zoledronic acid

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Congenital Dyserythropoietic Anemia (CDA)

    phase 2 small molecule active

    1 trial

  20. 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HPV Infection

    phase 1 mab completed

    1 trial

  21. 1mg KHK7580

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  22. 9MW3811 injection

    Shanghai University of Traditional Chinese Medicine

    Pulmonary Fibrosis

    phase 1 small molecule completed

    1 trial

  23. A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese and Japanese Participants, and Participants with Interstitial Lung Disease Associated with Connective Tissue Disease (CTD-ILD)

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  24. ASC30

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Weight Management

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources